Atonco’s Post

The first participant has been dosed with 68Ga-Trivehexin (RAD 301), a diagnostic radiopharmaceutical targeting αvβ6 integrin, for the detection of lesions in patients with Pancreatic Ductal Adenocarcinoma (PDAC): https://buff.ly/431zAmz The Phase I study of 9 participants is designed to assess the safety and dosimetry of RAD 301.

First important step towards better diagnostics for PDAC patients 💪

[Clinical Trials] Roche's phase 3 trial of Vabysmo reveals sustained retinal fluid dryness in CRVO and BRVO treatment https://lnkd.in/gC4pPu2g BridgeBio's Acoramidis Shows Positive Outcomes in Japan Phase III Trial for ATTR-CM https://lnkd.in/ga4qpnH9 [Deals] HUTCHMED announces Inmagene Biopharmaceuticals' exercise of licensing options for immunological drug candidates IMG-007 and IMG-004 https://lnkd.in/gvyDeund

#AACR24 BMS-986365, a Ligand Directed Androgen Receptor Degrader (AR LDD) #medicine First time disclosure from Shuichan Xu at New Drugs on the Horizon. Complete degradation! BMS-986365 (CC-94676) is an oral drug selectively targeting AR and induces effective and durable suppression of AR signaling, overcomes resistance to existing AR pathway inhibitors therapies and shows promising clinical activity in heavily pre-treated patients with mCRPC across wildtype, amplified and mutant AR status, highlighting this asset as the best-in-class AR-ligand directed degrader that may help overcome resistance to standard of care ARPIs in patients with mCRPC, a difficult-to-treat tumor type. #pharmaceuticals #healthcare Bristol Myers Squibb

Next CE Event! 🚨 This presentation will begin with a brief review of ocular surface disease, including definition, risk factors, and how to identify/diagnose. Followed by background on blepharitis (demodex), chalazion, and hordeolum. Particular emphasis will be placed on both 1) modern in-office therapeutic options (i.e. MBE, Thermal Expression, IPL, Amniotic Membrane) as well as 2) updated pharmaceutical options (ie immunomodulators, recently FDA-approved ophthalmic therapies, and new drugs in the pipeline). We will also discuss managing blepharitis with glaucoma patients. If time allows, we will cover Grand Rounds and patient cases. Register now! Here is the link: https://lnkd.in/gv7PPQxK #OcularSurfaceDisease #GlaucomaAwareness #EyeHealth #DryEyeSyndrome #VisionCare #Optometry #EyeConditions #GlaucomaTreatment #VisionTherapy

$MNPR - The results in both show near complete elimination of the tumor after a single injection of the radiopharmaceutical agent. These studies demonstrate the potential of a MNPR-101 based radiopharmaceutical to provide a very meaningful clinical benefit to patients. https://lnkd.in/ethsdXBY

Did you know that ACE inhibitors, vital in treating cardiovascular disease, have roots in snake venom? Dive into the captivating journey from serpent fangs to pharmaceutical breakthroughs, revolutionizing cardiovascular treatment. Discover the untapped potential of venom-based drugs for future medical marvels. Read our latest #PharmaRoots article here: https://okt.to/CtsqMR #CardiovascularHealth #SnakeVenomResearch #MedicalInnovation #PharmaRoots #ReferenceStandards

PF-07817883 (Ibuzatrelvir): A Second-Generation Main Protease Inhibitor with Improved Metabolic Stability | https://lnkd.in/g5SVBnBb PF-07817883 (ibuzatrelvir) is an oral, second-generation SARS-CoV-2 Mpro inhibitor developed by Pfizer. These efforts follow the success of Pfizer's antiviral combination drug, Paxlovid, which was granted Emergency Use Authorization by the FDA for the treatment of COVID-19 just 17 months after its first synthesis in July 2020. PF-07817883 was granted Fast Track designation and recently completed a Ph. II clinical trial to evaluate its safety and efficacy in outpatient adults with COVID-19 symptoms. This article details the discovery strategy for PF-07817883, which includes addressing metabolic soft spots identified through MetID studies, recent clinical developments, reviewer commentary, and more. Full Article: https://lnkd.in/g5SVBnBb

“EMA drafts concept paper for future radiopharmaceuticals guideline” Regulatory News | 15 October 2024 | By: Joanne Eglovitch #regulatoryaffairs #radiopharmaceuticalguidance #EMA #EMAguidance #conceptpaper

$HUMA Humacyte granted RMAT designation for Acellular Tissue Engineered Vessel Humacyte has been granted the U.S. Food and Drug Administration's Regenerative Medicine Advanced Therapy designation for patients with advanced peripheral artery disease. This RMAT designation is granted at the same time as FDA cleared a new Investigational New Drug application for the PAD indication for Humacyte's investigational Acellular Tissue Engineered Vessel, formerly referred to as the "HAV". The RMAT designation is designed to provide pathways for expedited development and review of regenerative medicine therapies for serious or life-threatening diseases or conditions. The designation allows for close interactions with the FDA and potentially an expedited/priority review of a Biologics License Application. This is the third RMAT designation granted by the FDA for Humacyte's ATEV, in addition to previous RMAT designations for vascular trauma repair and arteriovenous access in hemodialysis.